Pharmacology Research Today is a free monthly online journal that collates and summarizes the latest research about Pharmacology, including details on pharmacogenomics, drug development, new medications.

Volume 7 (2011), Issue 10 (October)

1. In silico design of small molecules.
   Methods Mol Biol, 800: 25-31. [Abstract] [Full-text]
2. Genomics reaches the clinic: from basic discoveries to clinical impact.
   Cell, 147(1): 14-6. [Abstract] [Full-text]
3. Systems genetics for drug target discovery.
   Trends Pharmacol Sci, 32(10): 623-30. [Abstract] [Full-text]
4. Characterization of new potential anticancer drugs designed to overcome glutathione transferase mediated resistance.
   Mol Pharm, 8(5): 1698-708. [Abstract] [Full-text]
5. The subcellular distribution of small molecules: from pharmacokinetics to synthetic biology.
   Mol Pharm, 8(5): 1619-28. [Abstract] [Full-text]
6. Thermodynamic and structural aspects of novel 1,2,4-thiadiazoles in solid and biological mediums.
   Mol Pharm, 8(5): 1807-20. [Abstract] [Full-text]
7. Large amino acid transporter 1 (LAT1) prodrugs of valproic acid: new prodrug design ideas for central nervous system delivery.
   Mol Pharm, 8(5): 1857-66. [Abstract] [Full-text]
8. A CXCL8 receptor antagonist based on the structure of N-acetyl-proline-glycine-proline.
   Eur J Pharmacol, 668(3): 435-42. [Abstract] [Full-text]
9. The significance of G protein-coupled receptor crystallography for drug discovery.
   Pharmacol Rev, 63(4): 901-37. [Abstract] [Full-text]
10. Design and synthesis of carbocyclic versions of furanoid nucleoside phosphonic Acid analogues as potential anti-hiv agents.
    Nucleosides Nucleotides Nucleic Acids, 30(10): 798-813. [Abstract] [Full-text]
11. Pharmaceutical cocrystals: an overview.
    Int J Pharm, 419(1): 1-11. [Abstract] [Full-text]
12. A quality by design (QbD) case study on liposomes containing hydrophilic API: I. Formulation, processing design and risk assessment.
    Int J Pharm, 419(1): 52-9. [Abstract] [Full-text]
13. Rational design and optimization of downstream processes of virus particles for biopharmaceutical applications: current advances.
    Biotechnol Adv, 29(6): 869-78. [Abstract] [Full-text]
14. Toxicology in the ICU: Part 2: specific toxins.
    Chest, 140(4): 1072-85. [Abstract] [Full-text]
15. Rational design of novel anti-microtubule agent (9-azido-noscapine) from quantitative structure activity relationship (QSAR) evaluation of noscapinoids.
    J Biomol Screen, 16(9): 1047-58. [Abstract] [Full-text]
16. Toxicologic pathology in a multicultural world--India.
    Toxicol Pathol, 39(6): 1003-9. [Abstract] [Full-text]
17. An assessment of three harpacticoid copepod species for use in ecotoxicological testing.
    Arch Environ Contam Toxicol, 61(3): 414-25. [Abstract] [Full-text]
18. A python-based docking program utilizing a receptor bound ligand shape: PythDock.
    Arch Pharm Res, 34(9): 1451-8. [Abstract] [Full-text]
19. Design and synthesis of new 1,4-dihydropyridines containing 4(5)-chloro-5(4)-imidazolyl substituent as a novel calcium channel blocker.
    Arch Pharm Res, 34(9): 1417-26. [Abstract] [Full-text]
20. Venoms as a platform for human drugs: translating toxins into therapeutics.
    Expert Opin Biol Ther, 11(11): 1469-84. [Abstract] [Full-text]
21. Chemical structural novelty: on-targets and off-targets.
    J Med Chem, 54(19): 6771-85. [Abstract] [Full-text]
22. Consideration of patient preferences and challenges in storage and access of pharmacogenetic test results.
    Genet Med, 13(10): 887-90. [Abstract] [Full-text]
23. Novel therapies targeting inner mitochondrial membrane--from discovery to clinical development.
    Pharm Res, 28(11): 2669-79. [Abstract] [Full-text]
24. Improving a natural CaMKII inhibitor by random and rational design.
    PLoS One, 6(10): e25245. [Abstract] [Full-text]
25. Synthesis, characterisation and biological evaluation of copper and silver complexes based on acetylsalicylic acid.
    Arch Pharm (Weinheim), 344(10): 684-8. [Abstract] [Full-text]
26. Synthesis of novel thiazolyl-pyrimidines and their anticancer activity in vitro.
    Arch Pharm (Weinheim), 344(10): 675-83. [Abstract] [Full-text]
27. Design, synthesis and antifungal activity of some new imidazole and triazole derivatives.
    Arch Pharm (Weinheim), 344(10): 658-65. [Abstract] [Full-text]
28. Anti-tumor activity of new artemisinin-chalcone hybrids.
    Arch Pharm (Weinheim), 344(10): 639-47. [Abstract] [Full-text]
29. The application of tandem aza-wittig reaction to synthesize artemisinin-guanidine hybrids and their anti-tumor activity.
    Arch Pharm (Weinheim), 344(10): 631-8. [Abstract] [Full-text]
30. Discovery of 1-arylcarbonyl-6,7-dimethoxyisoquinoline derivatives as glutamine fructose-6-phosphate amidotransferase (GFAT) inhibitors.
    Bioorg Med Chem Lett, 21(21): 6264-9. [Abstract] [Full-text]
31. Discovery and optimization of a biphenylacetic acid series of prostaglandin D2 receptor DP2 antagonists with efficacy in a murine model of allergic rhinitis.
    Bioorg Med Chem Lett, 21(21): 6608-12. [Abstract] [Full-text]
32. Discovery of novel 3,5-disubstituted indole derivatives as potent inhibitors of Pim-1, Pim-2, and Pim-3 protein kinases.
    Bioorg Med Chem Lett, 21(21): 6366-9. [Abstract] [Full-text]
33. Design, synthesis, and structure-activity relationships of spirolactones bearing 2-ureidobenzothiophene as acetyl-CoA carboxylases inhibitors.
    Bioorg Med Chem Lett, 21(21): 6314-8. [Abstract] [Full-text]
34. Substituted indole-1-acetic acids as potent and selective CRTh2 antagonists-discovery of AZD1981.
    Bioorg Med Chem Lett, 21(21): 6288-92. [Abstract] [Full-text]
35. Design and synthesis of a library of chemokine antagonists.
    Bioorg Med Chem Lett, 21(21): 6249-52. [Abstract] [Full-text]
36. Peptide-bound dinitrosyliron complexes (DNICs) and neutral/reduced-form Roussin's red esters (RREs/rRREs): understanding nitrosylation of [Fe-S] clusters leading to the formation of DNICs and RREs using a de novo design strategy.
    Inorg Chem, 50(20): 10417-31. [Abstract] [Full-text]
37. Design, synthesis and insight into the structure-activity relationship of 1,3-disubstituted indazoles as novel HIF-1 inhibitors.
    Bioorg Med Chem Lett, 21(21): 6297-300. [Abstract] [Full-text]
38. Design, synthesis, and biological evaluation of benzodiazepine-based SUMO-specific protease 1 inhibitors.
    Bioorg Med Chem Lett, 21(21): 6389-92. [Abstract] [Full-text]
39. Discovery of a novel series of cyclic urea as potent CCR5 antagonists.
    Bioorg Med Chem Lett, 21(21): 6381-5. [Abstract] [Full-text]
40. Fragment based discovery of a novel and selective PI3 kinase inhibitor.
    Bioorg Med Chem Lett, 21(21): 6586-90. [Abstract] [Full-text]
41. Discovery of novel spirocyclic inhibitors of fatty acid amide hydrolase (FAAH). Part 1: identification of 7-azaspiro[3.5]nonane and 1-oxa-8-azaspiro[4.5]decane as lead scaffolds.
    Bioorg Med Chem Lett, 21(21): 6538-44. [Abstract] [Full-text]
42. Discovery of novel spirocyclic inhibitors of fatty acid amide hydrolase (FAAH). Part 2. Discovery of 7-azaspiro[3.5]nonane urea PF-04862853, an orally efficacious inhibitor of fatty acid amide hydrolase (FAAH) for pain.
    Bioorg Med Chem Lett, 21(21): 6545-53. [Abstract] [Full-text]
43. Discovery of spiropiperidine-based potent and selective Orexin-2 receptor antagonists.
    Bioorg Med Chem Lett, 21(21): 6409-13. [Abstract] [Full-text]
44. Challenges of drug discovery in novel target space. The discovery and evaluation of PF-3893787: a novel histamine H4 receptor antagonist.
    Bioorg Med Chem Lett, 21(21): 6596-602. [Abstract] [Full-text]
45. Discovery of a novel potent GABA(B) receptor agonist.
    Bioorg Med Chem Lett, 21(21): 6582-5. [Abstract] [Full-text]
46. Discovery of potent, selective, orally active benzoxazepine-based Orexin-2 receptor antagonists.
    Bioorg Med Chem Lett, 21(21): 6414-6. [Abstract] [Full-text]
47. Modelling formulations using gene expression programming--a comparative analysis with artificial neural networks.
    Eur J Pharm Sci, 44(3): 366-74. [Abstract] [Full-text]
48. Synthesis and anti-bacterial activity of some heterocyclic chalcone derivatives bearing thiofuran, furan, and quinoline moieties.
    Arch Pharm (Weinheim), 344(10): 689-95. [Abstract] [Full-text]
49. Rapid allele-specific PCR method for CDA 79A>C (K27Q) genotyping: a useful pharmacogenetic tool and world-wide polymorphism distribution.
    Clin Chim Acta, 412(23): 2237-40. [Abstract] [Full-text]
50. Inter- and intra-laboratory study to determine the reproducibility of toxicogenomics datasets.
    Toxicology, 290(1): 50-8. [Abstract] [Full-text]
51. Interrogating health-related public databases from a food toxicology perspective: computational analysis of scoring data.
    Food Chem Toxicol, 49(11): 2830-40. [Abstract] [Full-text]
52. Current and future use of genomics data in toxicology: opportunities and challenges for regulatory applications.
    Regul Toxicol Pharmacol, 61(2): 141-53. [Abstract] [Full-text]
53. Refined analysis of antigen-specific antibody responses--a new one-step tool in immunogenicity studies.
    Eur J Pharm Sci, 44(3): 187-93. [Abstract] [Full-text]
54. A challenging drug development process in the era of personalized medicine.
    Drug Discov Today, 16(19): 891-7. [Abstract] [Full-text]
55. Pharmacogenomics: a new clinical or regulatory paradigm? European experiences of pharmacogenomics in drug regulation and regulatory initiatives.
    Drug Discov Today, 16(19): 867-72. [Abstract] [Full-text]
56. Considerations for safety pharmacogenetics in clinical practice.
    Drug Discov Today, 16(19): 898-901. [Abstract] [Full-text]
57. Discontinued drugs in 2010: oncology drugs.
    Expert Opin Investig Drugs, 20(11): 1479-96. [Abstract] [Full-text]
58. Design of prolonged release tablets using new solid acrylic excipients for direct compression.
    Eur J Pharm Biopharm, 79(3): 664-73. [Abstract] [Full-text]
59. European attitudes to gene therapy and pharmacogenetics.
    Drug Discov Today, 16(19): 843-7. [Abstract] [Full-text]
60. A conceptual framework for pharmacodynamic genome-wide association studies in pharmacogenomics.
    Drug Discov Today, 16(19): 884-90. [Abstract] [Full-text]
61. Pharmacogenetics and cost-effectiveness analysis: a two-way street.
    Drug Discov Today, 16(19): 873-7. [Abstract] [Full-text]
62. Drug-diagnostic co-development: how to harness the value.
    Drug Discov Today, 16(19): 902-5. [Abstract] [Full-text]
63. The biomarker is not the end.
    Drug Discov Today, 16(19): 878-83. [Abstract] [Full-text]
64. Pharmacogenetics: past, present and future.
    Drug Discov Today, 16(19): 852-61. [Abstract] [Full-text]
65. Pharmacogenetics: practices and opportunities for study design and data analysis.
    Drug Discov Today, 16(19): 862-6. [Abstract] [Full-text]
66. Glycosylation profiles of therapeutic antibody pharmaceuticals.
    Eur J Pharm Biopharm, 79(3): 503-7. [Abstract] [Full-text]
67. Prospective CCR5 small molecule antagonist compound design using a combined mutagenesis/modeling approach.
    J Am Chem Soc, 133(41): 16477-85. [Abstract] [Full-text]
68. Design, synthesis and biological evaluation of optically pure functionalized spiro[5,5]undecane-1,5,9-triones as HIV-1 inhibitors.
    Org Biomol Chem, 9(21): 7282-6. [Abstract] [Full-text]
69. Statins increase the risk of prostate cancer: a population-based case-control study.
    Prostate, 71(16): 1818-24. [Abstract] [Full-text]
70. Prescribed drugs and violence: a case/noncase study in the French PharmacoVigilance Database.
    Eur J Clin Pharmacol, 67(11): 1189-98. [Abstract] [Full-text]
71. Therapeutic potential of nucleic acid-binding isoquinoline alkaloids: binding aspects and implications for drug design.
    Med Res Rev, 31(6): 821-62. [Abstract] [Full-text]
72. Fabrication principles and their contribution to the superior in vivo therapeutic efficacy of nano-liposomes remote loaded with glucocorticoids.
    PLoS One, 6(10): e25721. [Abstract] [Full-text]
73. Discovery of diverse small molecule chemotypes with cell-based PKD1 inhibitory activity.
    PLoS One, 6(10): e25134. [Abstract] [Full-text]
74. Synthesis of bridgehead-substituted azabicyclo[2.2.1]heptane and -[3.3.1]nonane derivatives for the elaboration of α7 nicotinic ligands.
    J Org Chem, 76(20): 8336-46. [Abstract] [Full-text]
75. Palladium-catalyzed mono-N-allylation of unprotected anthranilic acids with allylic alcohols in aqueous media.
    J Org Chem, 76(20): 8433-9. [Abstract] [Full-text]
76. Domino reaction to functionalized 2-hydroxybenzophenones from electron-deficient chromones and 1,3-dicarbonyl compounds.
    J Org Chem, 76(20): 8495-500. [Abstract] [Full-text]
77. Stereoselective synthesis of cis-3,4-disubstituted piperidines through ring transformation of 2-(2-mesyloxyethyl)azetidines.
    J Org Chem, 76(20): 8364-75. [Abstract] [Full-text]
78. Synthesis of diastereomerically pure nucleotide phosphoramidates.
    J Org Chem, 76(20): 8311-9. [Abstract] [Full-text]
79. Stereospecific total syntheses of proteasome inhibitors omuralide and lactacystin.
    J Org Chem, 76(20): 8287-93. [Abstract] [Full-text]
80. Synthesis of fused imidazoles, pyrroles, and indoles with a defined stereocenter α to nitrogen utilizing Mitsunobu alkylation followed by palladium-catalyzed cyclization.
    J Org Chem, 76(20): 8477-82. [Abstract] [Full-text]
81. Palladium-catalyzed direct ortho C-H arylation of 2-arylpyridine derivatives with aryltrimethoxysilane.
    J Org Chem, 76(20): 8543-8. [Abstract] [Full-text]
82. Neoteric pharmacotherapeutic targets in fibromyalgia.
    Expert Opin Ther Targets, 15(11): 1267-81. [Abstract] [Full-text]
83. Divergent regioselective synthesis of 2,5,6,7-tetrahydro-1H-1,4-diazepin-2-ones and 5H-1,4-benzodiazepines.
    J Org Chem, 76(20): 8320-8. [Abstract] [Full-text]
84. Quinoxalino[2,3-c]cinnolines and their 5-N-oxide: alkoxylation of methyl-substituted quinoxalino[2,3-c]cinnolines to acetals and orthoesters.
    J Org Chem, 76(20): 8421-7. [Abstract] [Full-text]
85. Synthesis of 2- and 2,3-substituted pyrazolo[1,5-a]pyridines: scope and mechanistic considerations of a domino direct alkynylation and cyclization of N-iminopyridinium ylides using alkenyl bromides, alkenyl iodides, and alkynes.
    J Org Chem, 76(20): 8243-61. [Abstract] [Full-text]
86. Synthesis of benzothiophene derivatives by Pd-catalyzed or radical-promoted heterocyclodehydration of 1-(2-mercaptophenyl)-2-yn-1-ols.
    J Org Chem, 76(20): 8277-86. [Abstract] [Full-text]
87. Structure of the lycorinine alkaloid nobilisitine A.
    J Org Chem, 76(20): 8560-3. [Abstract] [Full-text]
88. Direct, metal-free amination of heterocyclic amides/ureas with NH-heterocycles and N-substituted anilines in POCl3.
    J Org Chem, 76(20): 8262-9. [Abstract] [Full-text]
89. Representation of multi-target activity landscapes through target pair-based compound encoding in self-organizing maps.
    Chem Biol Drug Des, 78(5): 778-86. [Abstract] [Full-text]
90. Methods for the preparation of allenes employing indium- and zinc-mediated dehalogenation reactions in aqueous solutions.
    J Org Chem, 76(20): 8518-23. [Abstract] [Full-text]
91. Asymmetric Michael addition of malonates to enones catalyzed by a primary β-amino acid and its lithium salt.
    J Org Chem, 76(20): 8513-7. [Abstract] [Full-text]
92. Sc(OTf)3-catalyzed synthesis of indoles and SnCl4-mediated regioselective hydrochlorination of 5-(arylamino)pent-3-yn-2-ones.
    J Org Chem, 76(20): 8329-35. [Abstract] [Full-text]
93. Palladium-catalyzed amination of allyl alcohols.
    J Org Chem, 76(20): 8508-12. [Abstract] [Full-text]
94. Regioselective copper-mediated synthesis of thieno[2,3-c]pyrane-7-one, indolo[2,3-c]pyrane-1-one, and indolo[3,2-c]pyrane-1-one.
    J Org Chem, 76(20): 8347-54. [Abstract] [Full-text]
95. The antibiotic R&D pipeline: an update.
    Curr Opin Microbiol, 14(5): 564-9. [Abstract] [Full-text]
96. Is bacterial fatty acid synthesis a valid target for antibacterial drug discovery?
    Curr Opin Microbiol, 14(5): 544-9. [Abstract] [Full-text]
97. 1-[(2-arylthiazol-4-yl)methyl]azoles as a new class of anticonvulsants: design, synthesis, in vivo screening, and in silico drug-like properties.
    Chem Biol Drug Des, 78(5): 844-52. [Abstract] [Full-text]
98. New tuberculosis drugs on the horizon.
    Curr Opin Microbiol, 14(5): 570-6. [Abstract] [Full-text]
99. Antibiotics and the post-genome revolution.
    Curr Opin Microbiol, 14(5): 513-8. [Abstract] [Full-text]
100. Rational design of peptides with anti-HCV/HIV activities and enhanced specificity.
     Chem Biol Drug Des, 78(5): 835-43. [Abstract] [Full-text]
101. Pharmacophore optimization and design of competitive inhibitors of thymidine monophosphate kinase through molecular modeling studies.
     Chem Biol Drug Des, 78(5): 826-34. [Abstract] [Full-text]
102. Rearrangement of 3-deoxy-D-erythro-hexos-2-ulose in aqueous solution: NMR evidence of intramolecular 1,2-hydrogen transfer.
     J Org Chem, 76(20): 8151-8. [Abstract] [Full-text]
103. Design, synthesis and structure of novel para-quinones and their antibacterial activity.
     Chem Biol Drug Des, 78(5): 787-99. [Abstract] [Full-text]
104. Enantioselective organocatalytic Friedel-Crafts alkylation reaction of indoles with 5-hydroxyfuran-2(5H)-one: access to chiral γ-lactones and γ-lactams via a Ugi 4-center 3-component reaction.
     J Org Chem, 76(20): 8143-50. [Abstract] [Full-text]
105. Can molecular dynamics simulations assist in design of specific inhibitors and imaging agents of amyloid aggregation? Structure, stability and free energy predictions for amyloid oligomers of VQIVYK, MVGGVV and LYQLEN.
     J Mol Model, 17(10): 2423-42. [Abstract] [Full-text]
106. Ligand-directed functional selectivity at the mu opioid receptor revealed by label-free integrative pharmacology on-target.
     PLoS One, 6(10): e25643. [Abstract] [Full-text]
107. Rapid analysis of isomeric exogenous metabolites by differential mobility spectrometry-mass spectrometry.
     Rapid Commun Mass Spectrom, 25(22): 3382-6. [Abstract] [Full-text]
108. Multi-target drug discovery in anti-cancer therapy: fragment-based approach toward the design of potent and versatile anti-prostate cancer agents.
     Bioorg Med Chem, 19(21): 6239-44. [Abstract] [Full-text]
109. An update on ethnic differences in drug metabolism and toxicity from anti-cancer drugs.
     Expert Opin Drug Metab Toxicol, 7(11): 1395-410. [Abstract] [Full-text]
110. Cellular uptake of cyclotide MCoTI-I follows multiple endocytic pathways.
     J Control Release, 155(2): 134-43. [Abstract] [Full-text]
111. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications.
     Int J Pharm, 420(1): 1-10. [Abstract] [Full-text]
112. Targeting microRNAs involved in human diseases: a novel approach for modification of gene expression and drug development.
     Biochem Pharmacol, 82(10): 1416-29. [Abstract] [Full-text]
113. Development of biotic ligand models for chronic manganese toxicity to fish, invertebrates, and algae.
     Environ Toxicol Chem, 30(11): 2407-15. [Abstract] [Full-text]
114. Engineering and screening the N-terminus of chemokines for drug discovery.
     Biochem Pharmacol, 82(10): 1438-56. [Abstract] [Full-text]
115. Toxicokinetic-toxicodynamic modeling of quantal and graded sublethal endpoints: a brief discussion of concepts.
     Environ Toxicol Chem, 30(11): 2519-24. [Abstract] [Full-text]
116. Theoretical study of GSK-3α: neural networks QSAR studies for the design of new inhibitors using 2D descriptors.
     Mol Divers, 15(4): 947-55. [Abstract] [Full-text]
117. Patent pools and clearinghouses in the life sciences.
     Trends Biotechnol, 29(11): 569-76. [Abstract] [Full-text]
118. Development of docetaxel-loaded intravenous formulation, Nanoxel-PM™ using polymer-based delivery system.
     J Control Release, 155(2): 262-71. [Abstract] [Full-text]
119. Design of multi-drug release coatings targeting infection and inflammation.
     J Control Release, 155(2): 159-66. [Abstract] [Full-text]
120. Design and cellular internalization of genetically engineered polypeptide nanoparticles displaying adenovirus knob domain.
     J Control Release, 155(2): 218-26. [Abstract] [Full-text]
121. QSAR model toward the rational design of new agrochemical fungicides with a defined resistance risk using substructural descriptors.
     Mol Divers, 15(4): 901-9. [Abstract] [Full-text]
122. New pharmaceutical applications for macromolecular binders.
     J Control Release, 155(2): 200-10. [Abstract] [Full-text]
123. An integrated drug-likeness study for bicyclic privileged structures: from physicochemical properties to in vitro ADME properties.
     Mol Divers, 15(4): 857-76. [Abstract] [Full-text]
124. Insights into the binding modes of human β₃-adrenergic receptor agonists with ligand-based and receptor-based methods.
     Mol Divers, 15(4): 817-31. [Abstract] [Full-text]
125. Optical imaging for the new grammar of drug discovery.
     Philos Transact A Math Phys Eng Sci, 369(1955): 4651-65. [Abstract] [Full-text]
126. Toward rational design of protein detergent complexes: determinants of mixed micelles that are critical for the in vitro stabilization of a G-protein coupled receptor.
     Biophys J, 101(8): 1938-48. [Abstract] [Full-text]
127. Emerging role of surface plasmon resonance in fragment-based drug discovery.
     Future Med Chem, 3(14): 1809-20. [Abstract] [Full-text]
128. Medicinal chemistry for 2020.
     Future Med Chem, 3(14): 1765-86. [Abstract] [Full-text]
129. Vibrio cholerae infection, novel drug targets and phage therapy.
     Future Microbiol, 6(10): 1199-208. [Abstract] [Full-text]
130. Occupational toxicology in Mexico: current status and the potential use of molecular studies to evaluate chemical exposure.
     Toxicol Mech Methods, 21(9): 637-48. [Abstract] [Full-text]
131. Current and future needs for developmental toxicity testing.
     Birth Defects Res B Dev Reprod Toxicol, 92(5): 384-94. [Abstract] [Full-text]
132. Solid dispersions, part I: recent evolutions and future opportunities in manufacturing methods for dissolution rate enhancement of poorly water-soluble drugs.
     Expert Opin Drug Deliv, 8(11): 1501-19. [Abstract] [Full-text]
133. Natural products and Pharma 2011: strategic changes spur new opportunities.
     Nat Prod Rep, 28(11): 1783-9. [Abstract] [Full-text]
134. Validation of USP apparatus 4 method for microsphere in vitro release testing using Risperdal Consta.
     Int J Pharm, 420(2): 198-205. [Abstract] [Full-text]
135. New and unusual scaffolds in medicinal chemistry.
     Chem Soc Rev, 40(11): 5514-33. [Abstract] [Full-text]
136. Sensitivity of spore germination and germ tube elongation of Saccharina japonica to metal exposure.
     Ecotoxicology, 20(8): 2056-68. [Abstract] [Full-text]
137. Overview: developmental toxicology: new directions.
     Birth Defects Res B Dev Reprod Toxicol, 92(5): 381-3. [Abstract] [Full-text]
138. Combinatorial-designed multifunctional polymeric nanosystems for tumor-targeted therapeutic delivery.
     Acc Chem Res, 44(10): 1009-17. [Abstract] [Full-text]
139. Supramolecular nanodevices: from design validation to theranostic nanomedicine.
     Acc Chem Res, 44(10): 999-1008. [Abstract] [Full-text]
140. Outdoor Terrestrial Model Ecosystems are suitable to detect pesticide effects on soil fauna: design and method development.
     Ecotoxicology, 20(8): 1932-48. [Abstract] [Full-text]
141. Ecotoxicological diagnosis of striped dolphin (Stenella coeruleoalba) from the Mediterranean basin by skin biopsy and gene expression approach.
     Ecotoxicology, 20(8): 1791-800. [Abstract] [Full-text]
142. Cardiac specific effects of thyroid hormone analogues.
     Horm Metab Res, 43(11): 737-42. [Abstract] [Full-text]
143. Molecular toxicology of corals: a review.
     J Toxicol Environ Health B Crit Rev, 14(8): 571-92. [Abstract] [Full-text]
144. Pharmacogenetics in randomized controlled trials: considerations for trial design.
     Pharmacogenomics, 12(10): 1485-92. [Abstract] [Full-text]
145. Recent progress and clinical importance on pharmacogenetics in cancer therapy.
     Clin Chem Lab Med, 49(10): 1621-32. [Abstract] [Full-text]
146. Trivalent PEGylated platform for the conjugation of bioactive compounds.
     Bioconjug Chem, 22(10): 2172-8. [Abstract] [Full-text]
147. Utilizing drug-drug interaction prediction tools during drug development: enhanced decision making based on clinical risk.
     Drug Metab Dispos, 39(11): 2076-84. [Abstract] [Full-text]
148. Computational vaccinology: an important strategy to discover new potential S. mansoni vaccine candidates.
     J Biomed Biotechnol, 2011: 503068. [Abstract] [Full-text]
149. Considerations regarding nonhuman primate use in safety assessment of biopharmaceuticals.
     Int J Toxicol, 30(5): 583-90. [Abstract] [Full-text]
150. Isolation of rat embryonic stem-like cells: a tool for stem cell research and drug discovery.
     Dev Dyn, 240(11): 2482-94. [Abstract] [Full-text]
151. Pharmacogenetic approaches to the treatment of alcohol addiction.
     Nat Rev Neurosci, 12(11): 670-84. [Abstract] [Full-text]
152. Plant use in Odo-Bulu and Demaro, Bale region, Ethiopia.
     J Ethnobiol Ethnomed, 7: 28. [Abstract] [Full-text]
153. The role of the toxicologic pathologist in the biopharmaceutical industry.
     Int J Toxicol, 30(5): 568-82. [Abstract] [Full-text]
154. Drug design structural alert: formation of trifluoroacetaldehyde through N-dealkylation is linked to testicular lesions in rat.
     Int J Toxicol, 30(5): 546-50. [Abstract] [Full-text]
155. Design and synthesis of CK2 inhibitors.
     Mol Cell Biochem, 356(1): 91-6. [Abstract] [Full-text]
156. Structure-based discovery of novel flavonol inhibitors of human protein kinase CK2.
     Mol Cell Biochem, 356(1): 107-15. [Abstract] [Full-text]
157. Effect of ABCB1 and ABCC3 polymorphisms on osteosarcoma survival after chemotherapy: a pharmacogenetic study.
     PLoS One, 6(10): e26091. [Abstract] [Full-text]
158. Viscosity of concentrated therapeutic protein compositions.
     Adv Drug Deliv Rev, 63(13): 1107-17. [Abstract] [Full-text]
159. A modular approach to trim cellular targets in anticancer drug discovery.
     Bioorg Med Chem Lett, 21(22): 6641-5. [Abstract] [Full-text]
160. A double prodrug system for colon targeting of benzenesulfonamide COX-2 inhibitors.
     Bioorg Med Chem Lett, 21(22): 6636-40. [Abstract] [Full-text]
161. One-class classification as a novel method of ligand-based virtual screening: the case of glycogen synthase kinase 3β inhibitors.
     Bioorg Med Chem Lett, 21(22): 6728-31. [Abstract] [Full-text]
162. Design, synthesis, and SAR studies of novel polycyclic acids as potent and selective inhibitors of human 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD-1).
     Bioorg Med Chem Lett, 21(22): 6699-704. [Abstract] [Full-text]
163. A novel potential therapeutic avenue for autism: design, synthesis and pharmacophore generation of SSRIs with dual action.
     Bioorg Med Chem Lett, 21(22): 6714-23. [Abstract] [Full-text]
164. Computational techniques are valuable tools for the discovery of protein-protein interaction inhibitors: the 14-3-3σ case.
     Bioorg Med Chem Lett, 21(22): 6867-71. [Abstract] [Full-text]
165. Protein-excipient interactions: mechanisms and biophysical characterization applied to protein formulation development.
     Adv Drug Deliv Rev, 63(13): 1118-59. [Abstract] [Full-text]
166. Activity-based protein profiling of protein arginine methyltransferase 1.
     ACS Chem Biol, 6(10): 1127-35. [Abstract] [Full-text]
167. Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons.
     ACS Chem Biol, 6(10): 1021-8. [Abstract] [Full-text]
168. Molecular origins of surfactant-mediated stabilization of protein drugs.
     Adv Drug Deliv Rev, 63(13): 1160-71. [Abstract] [Full-text]
169. A human TREK-1/HEK cell line: a highly efficient screening tool for drug development in neurological diseases.
     PLoS One, 6(10): e25602. [Abstract] [Full-text]
170. Sudden death in epilepsy: standards of reporting and the value of toxicological analysis.
     J Clin Pathol, 64(11): 1025-8. [Abstract] [Full-text]
171. Selective PI3Kδ inhibitors, a review of the patent literature.
     Expert Opin Ther Pat, 21(11): 1773-90. [Abstract] [Full-text]
172. Recent patents on therapeutic applications of the transcription factor decoy approach.
     Expert Opin Ther Pat, 21(11): 1755-71. [Abstract] [Full-text]
173. Norcantharidin analogues: a patent review (2006 - 2010).
     Expert Opin Ther Pat, 21(11): 1743-53. [Abstract] [Full-text]
174. Novel thyrotropin-releasing hormone analogs: a patent review.
     Expert Opin Ther Pat, 21(11): 1673-91. [Abstract] [Full-text]
175. Cyclotides: a patent review.
     Expert Opin Ther Pat, 21(11): 1657-72. [Abstract] [Full-text]
176. 1-Aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamide: an effective scaffold for the design of either CB1 or CB2 receptor ligands.
     Eur J Med Chem, 46(11): 5641-53. [Abstract] [Full-text]
177. Novel platinum(II) and palladium(II) complexes of thiosemicarbazones derived from 5-substitutedthiophene-2-carboxaldehydes and their antiviral and cytotoxic activities.
     Eur J Med Chem, 46(11): 5616-24. [Abstract] [Full-text]
178. Ligustrazine derivatives. Part 5: design, synthesis and biological evaluation of novel ligustrazinyloxy-cinnamic acid derivatives as potent cardiovascular agents.
     Eur J Med Chem, 46(11): 5609-15. [Abstract] [Full-text]
179. Docking studies of benzylidene anabaseine interactions with α7 nicotinic acetylcholine receptor (nAChR) and acetylcholine binding proteins (AChBPs): application to the design of related α7 selective ligands.
     Eur J Med Chem, 46(11): 5625-35. [Abstract] [Full-text]
180. A class of novel N-(1-methyl-β-carboline-3-carbonyl)-N'-(aminoacid-acyl)-hydrazines: aromatization leaded design, synthesis, in vitro anti-platelet aggregation/in vivo anti-thrombotic evaluation and 3D QSAR analysis.
     Eur J Med Chem, 46(11): 5598-608. [Abstract] [Full-text]
181. Design and synthesis of novel triazole antifungal derivatives by structure-based bioisosterism.
     Eur J Med Chem, 46(11): 5276-82. [Abstract] [Full-text]
182. L-Proline anchored multicomponent synthesis of novel pyrido[2,3-a]carbazoles; investigation of in vitro antimicrobial, antioxidant, cytotoxicity and structure activity relationship studies.
     Eur J Med Chem, 46(11): 5580-90. [Abstract] [Full-text]
183. Design, synthesis and antibacterial activity of fluoroquinolones containing bulky arenesulfonyl fragment: 2D-QSAR and docking study.
     Eur J Med Chem, 46(11): 5487-97. [Abstract] [Full-text]
184. 1,3-Dihydro-2H-indol-2-ones derivatives: design, synthesis, in vitro antibacterial, antifungal and antitubercular study.
     Eur J Med Chem, 46(11): 5573-9. [Abstract] [Full-text]
185. Synthesis and structure-activity relationship studies of 4-arylthiosemicarbazides as topoisomerase IV inhibitors with Gram-positive antibacterial activity. Search for molecular basis of antibacterial activity of thiosemicarbazides.
     Eur J Med Chem, 46(11): 5717-26. [Abstract] [Full-text]
186. 3-Hydroxy-6,7-dihydropyrimido[2,1-c][1,4]oxazin-4(9H)-ones as new HIV-1 integrase inhibitors WO2011046873 A1.
     Expert Opin Ther Pat, 21(11): 1799-804. [Abstract] [Full-text]
187. A novel glycosaminoglycan-like polysaccharide from abalone Haliotis discus hannai Ino: purification, structure identification and anticoagulant activity.
     Int J Biol Macromol, 49(5): 1160-6. [Abstract] [Full-text]
188. New 5-benzylidenethiazolidin-4-one inhibitors of bacterial MurD ligase: design, synthesis, crystal structures, and biological evaluation.
     Eur J Med Chem, 46(11): 5512-23. [Abstract] [Full-text]
189. In vitro antioxidant and radical-scavenging capacities of Citrullus colocynthes (L) and Artemisia absinthium extracts using promethazine hydrochloride radical cation and contemporary assays.
     Food Sci Technol Int, 17(5): 481-94. [Abstract] [Full-text]
190. Molecular design of new sodium channel blockers.
     Biochem Biophys Res Commun, 414(2): 321-5. [Abstract] [Full-text]
191. Carboxymethylation of polysaccharides from Auricularia auricula and their antioxidant activities in vitro.
     Int J Biol Macromol, 49(5): 1124-30. [Abstract] [Full-text]
192. Novel 1,5-naphthyridine PI3Kδ inhibitors, an evaluation of WO2011075628.
     Expert Opin Ther Pat, 21(11): 1805-10. [Abstract] [Full-text]
193. Design and synthesis of 2-(1, 3-dioxoisoindolin-2-yl)-N-(4-oxo-2-substitutedthiazolidin-3-yl) acetamide derivatives as potential anticonvulsant agents.
     Eur J Med Chem, 46(11): 5448-55. [Abstract] [Full-text]
194. Chemical analysis and antioxidant activity in vitro of polysaccharides extracted from Boletus edulis.
     Int J Biol Macromol, 49(5): 1092-5. [Abstract] [Full-text]
195. Exploiting the lipoic acid structure in the search for novel multitarget ligands against Alzheimer's disease.
     Eur J Med Chem, 46(11): 5435-42. [Abstract] [Full-text]
196. Design, synthesis and primary activity assay of tripeptidomimetics as histone deacetylase inhibitors with linear linker and branched cap group.
     Eur J Med Chem, 46(11): 5387-97. [Abstract] [Full-text]
197. Jack bean α-mannosidase (Jbα-man): tolerance to alkali, chelating and reducing agents and energetics of catalysis and inhibition.
     Int J Biol Macromol, 49(5): 1066-71. [Abstract] [Full-text]
198. LigPlot+: multiple ligand-protein interaction diagrams for drug discovery.
     J Chem Inf Model, 51(10): 2778-86. [Abstract] [Full-text]
199. CrystalDock: a novel approach to fragment-based drug design.
     J Chem Inf Model, 51(10): 2573-80. [Abstract] [Full-text]
200. Pocket-space maps to identify novel binding-site conformations in proteins.
     J Chem Inf Model, 51(10): 2666-79. [Abstract] [Full-text]
201. Design, synthesis and docking studies of new quinoline-3-carbohydrazide derivatives as antitubercular agents.
     Eur J Med Chem, 46(11): 5283-92. [Abstract] [Full-text]
202. Comparing bioassay response and similarity ensemble approaches to probing protein pharmacology.
     Bioinformatics, 27(21): 3044-9. [Abstract] [Full-text]
203. Polymer hydrogel from carboxymethyl guar gum and carbon nanotube for sustained trans-dermal release of diclofenac sodium.
     Int J Biol Macromol, 49(5): 885-93. [Abstract] [Full-text]
204. In vitro antioxidant activities of sulfated polysaccharide fractions extracted from Corallina officinalis.
     Int J Biol Macromol, 49(5): 1031-7. [Abstract] [Full-text]
205. Gaussian interaction profile kernels for predicting drug-target interaction.
     Bioinformatics, 27(21): 3036-43. [Abstract] [Full-text]
206. Synthesized oversulfated and acetylated derivatives of polysaccharide extracted from Enteromorpha linza and their potential antioxidant activity.
     Int J Biol Macromol, 49(5): 1012-5. [Abstract] [Full-text]
207. Purification and physicochemical properties of different polysaccharide fractions from the water extract of Boschniakia rossica and their effect on macrophages activation.
     Int J Biol Macromol, 49(5): 1007-11. [Abstract] [Full-text]
208. Encapsulation of probiotic Bifidobacterium longum BIOMA 5920 with alginate-human-like collagen and evaluation of survival in simulated gastrointestinal conditions.
     Int J Biol Macromol, 49(5): 979-84. [Abstract] [Full-text]
209. Formulation optimization of chelerythrine loaded O-carboxymethylchitosan microspheres using response surface methodology.
     Int J Biol Macromol, 49(5): 970-8. [Abstract] [Full-text]
210. Discovery of novel promising targets for anti-AIDS drug developments by computer modeling: application to the HIV-1 gp120 V3 loop.
     J Chem Inf Model, 51(10): 2760-7. [Abstract] [Full-text]
211. Combined approach using ligand efficiency, cross-docking, and antitarget hits for wild-type and drug-resistant Y181C HIV-1 reverse transcriptase.
     J Chem Inf Model, 51(10): 2595-611. [Abstract] [Full-text]
212. Optimization of polysaccharides extraction from Tetrastigma hemsleyanum Diels et Gilg using response surface methodology.
     Int J Biol Macromol, 49(5): 958-62. [Abstract] [Full-text]
213. Failure of pharmacogenetic-based dosing algorithms to identify older patients requiring low daily doses of warfarin.
     J Am Med Dir Assoc, 12(9): 633-8. [Abstract] [Full-text]
214. Same sex, no sex, and unaware sex in neurotoxicology.
     Neurotoxicology, 32(5): 509-17. [Abstract] [Full-text]
215. Pharmacogenetic predictors of methylphenidate dose-response in attention-deficit/hyperactivity disorder.
     J Am Acad Child Adolesc Psychiatry, 50(11): 1129-1139.e2. [Abstract] [Full-text]
216. Analysis, biomedicine, collaboration, and determinism challenges and guidance: wish list for biopharmaceuticals on the interface of computing and statistics.
     J Biopharm Stat, 21(6): 1140-57. [Abstract] [Full-text]
217. Ask the experts: future of the pharmaceutical industry. Interview by Future Medicinal Chemistry.
     Future Med Chem, 3(15): 1863-72. [Abstract] [Full-text]
218. Therapeutic effects of PEGylated insulin-like growth factor I in the pmn mouse model of motoneuron disease.
     Exp Neurol, 232(2): 261-9. [Abstract] [Full-text]
219. A model to incorporate genetic testing (5-HTTLPR) in pharmacological treatment of major depressive disorders.
     World J Biol Psychiatry, 12(7): 501-15. [Abstract] [Full-text]
220. Identification and characterization of mechanism of action of P61-E7, a novel phosphine catalysis-based inhibitor of geranylgeranyltransferase-I.
     PLoS One, 6(10): e26135. [Abstract] [Full-text]
221. A high-throughput platform for low-volume high-temperature/pressure sealed vessel solvent extractions.
     Anal Chim Acta, 707(1): 76-83. [Abstract] [Full-text]
222. In-line monitoring of alcohol precipitation by near-infrared spectroscopy in conjunction with multivariate batch modeling.
     Anal Chim Acta, 707(1): 47-56. [Abstract] [Full-text]
223. Epidemiological characterization of drug overconsumption: the example of antidepressants.
     J Addict Dis, 30(4): 342-50. [Abstract] [Full-text]
224. Use of the self-controlled case-series method in vaccine safety studies: review and recommendations for best practice.
     Epidemiol Infect, 139(12): 1805-17. [Abstract] [Full-text]
225. Protolimonoids and norlimonoids from the stem bark of Toona ciliata var. pubescens.
     Org Biomol Chem, 9(22): 7685-96. [Abstract] [Full-text]
226. A radical cyclization approach to the formal total syntheses of platencin.
     Org Biomol Chem, 9(22): 7877-86. [Abstract] [Full-text]
227. Cu(I)-catalyzed tandem benzyldiazoester coupling with terminal alkyne-allene formation-Michael reaction: application to the syntheses of oxa and azacycles.
     Org Biomol Chem, 9(22): 7913-20. [Abstract] [Full-text]
228. Scope of the organocatalysed asymmetric reductive amination of ketones with trichlorosilane.
     Org Biomol Chem, 9(22): 7860-8. [Abstract] [Full-text]
229. The challenge of the lantibiotics: synthetic approaches to thioether-bridged peptides.
     Org Biomol Chem, 9(22): 7606-28. [Abstract] [Full-text]
230. PtI2-catalyzed tandem 3,3-rearrangement/Nazarov reaction of arylpropargylic esters: synthesis of indanone derivatives.
     Org Biomol Chem, 9(22): 7755-62. [Abstract] [Full-text]
231. Regioselective and stereoselective cyclizations of cyclohexadienones tethered to active methylene groups.
     Org Biomol Chem, 9(22): 7849-59. [Abstract] [Full-text]
232. Organocatalytic enantioselective formal synthesis of bromopyrrole alkaloids via aza-Michael addition.
     Org Biomol Chem, 9(22): 7734-41. [Abstract] [Full-text]
233. Synthesis of uronic-noeurostegine--a potent bacterial β-glucuronidase inhibitor.
     Org Biomol Chem, 9(22): 7807-13. [Abstract] [Full-text]
234. Reactivity of acyclic (pentadienyl)iron(1+) cations: synthetic studies directed toward the frondosins.
     Org Biomol Chem, 9(22): 7742-7. [Abstract] [Full-text]
235. A concise stereoselective synthesis of (-)-erycibelline.
     Org Biomol Chem, 9(22): 7713-9. [Abstract] [Full-text]
236. Brønsted acid assisted activation of imide carbonyl group: regioselective synthesis of isoindoloisoquinolinone alkaloid (±)-nuevamine.
     Org Biomol Chem, 9(22): 7643-6. [Abstract] [Full-text]
237. Palladium-catalyzed desulfitative C-H arylation of azoles with sodium sulfinates.
     Org Biomol Chem, 9(22): 7675-9. [Abstract] [Full-text]
238. Synthesis and activity of the archazolid western hemisphere.
     Org Biomol Chem, 9(22): 7671-4. [Abstract] [Full-text]
239. Treatment of chronic heart failure with β-adrenergic receptor antagonists: a convergence of receptor pharmacology and clinical cardiology.
     Circ Res, 109(10): 1176-94. [Abstract] [Full-text]
240. Advancing drug discovery for schizophrenia.
     Ann N Y Acad Sci, 1236: 30-43. [Abstract] [Full-text]
241. Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases.
     Blood, 118(17): 4705-13. [Abstract] [Full-text]
242. Anti-inflammatory and antinociceptive activities of indole-imidazolidine derivatives.
     Int Immunopharmacol, 11(11): 1816-22. [Abstract] [Full-text]
243. Clinical pharmacology as a cornerstone of orphan drug development.
     Nat Rev Drug Discov, 10(11): 795-6. [Abstract] [Full-text]
244. Molecular dynamics simulations and drug discovery.
     BMC Biol, 9: 71. [Abstract] [Full-text]
245. Convergent pathogenic pathways in Alzheimer's and Huntington's diseases: shared targets for drug development.
     Nat Rev Drug Discov, 10(11): 853-67. [Abstract] [Full-text]
246. Towards a renewed research agenda in ecotoxicology.
     Environ Pollut, 160(1): 201-6. [Abstract] [Full-text]
247. Developmental toxicity testing in the 21st century: the sword of Damocles shattered by embryonic stem cell assays?
     Arch Toxicol, 85(11): 1361-72. [Abstract] [Full-text]
248. Synthesis, antimicrobial and antiproliferative activity of novel silver(I) tris(pyrazolyl)methanesulfonate and 1,3,5-triaza-7-phosphadamantane complexes.
     Inorg Chem, 50(21): 11173-83. [Abstract] [Full-text]
249. Tris(triazolyl) calix[6]arene-based zinc and copper funnel complexes: imidazole-like or pyridine-like? A comparative study.
     Inorg Chem, 50(21): 10985-93. [Abstract] [Full-text]
250. Titanocene-phosphine derivatives as precursors to cytotoxic heterometallic TiAu2 and TiM (M = Pd, Pt) compounds. Studies of their interactions with DNA.
     Inorg Chem, 50(21): 11099-110. [Abstract] [Full-text]
251. Extending the applicability of pressurized hot water extraction to compounds exhibiting limited water solubility by pH control: curcumin from the turmeric rhizome.
     Anal Bioanal Chem, 401(9): 2977-85. [Abstract] [Full-text]
252. Neonatal drug development.
     Early Hum Dev, 87(11): 763-8. [Abstract] [Full-text]
253. Influence of MRP2 on MPA pharmacokinetics in renal transplant recipients-results of the Pharmacogenomic Substudy within the Symphony Study.
     Nephrol Dial Transplant, 26(11): 3784-93. [Abstract] [Full-text]
254. Bioconversion of herbal industry waste into vermicompost using an epigeic earthworm Eudrilus eugeniae.
     Waste Manag Res, 29(11): 1205-12. [Abstract] [Full-text]

© 2005-2013 Pharmacology Research Today. All Rights Reserved.